Harbor Capital Advisors Inc. Boosts Stock Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Harbor Capital Advisors Inc. grew its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 299.9% during the third quarter, Holdings Channel reports. The institutional investor owned 1,027,738 shares of the company’s stock after purchasing an additional 770,744 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in MiMedx Group were worth $6,074,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Headlands Technologies LLC purchased a new stake in MiMedx Group in the first quarter worth about $27,000. Russell Investments Group Ltd. grew its stake in MiMedx Group by 5.0% in the first quarter. Russell Investments Group Ltd. now owns 551,546 shares of the company’s stock worth $4,247,000 after purchasing an additional 26,487 shares during the period. Isthmus Partners LLC raised its holdings in MiMedx Group by 39.4% in the first quarter. Isthmus Partners LLC now owns 301,500 shares of the company’s stock worth $2,322,000 after purchasing an additional 85,289 shares in the last quarter. ProShare Advisors LLC lifted its position in MiMedx Group by 8.5% during the first quarter. ProShare Advisors LLC now owns 20,735 shares of the company’s stock valued at $160,000 after buying an additional 1,631 shares during the period. Finally, Entropy Technologies LP bought a new stake in shares of MiMedx Group during the 1st quarter valued at $99,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Stock Performance

MDXG stock opened at $6.93 on Monday. The stock’s 50 day simple moving average is $6.06 and its 200 day simple moving average is $6.67. The company has a current ratio of 4.10, a quick ratio of 3.22 and a debt-to-equity ratio of 0.10. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $9.27. The stock has a market capitalization of $1.02 billion, a PE ratio of 12.60 and a beta of 1.94.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on MDXG shares. Craig Hallum lowered their price target on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. StockNews.com upgraded shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Thursday. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $11.00 price target on shares of MiMedx Group in a research note on Thursday, August 1st. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $12.00.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.